Opioid agonist and antagonist bivalent ligands as receptor probes.
about
A bivalent ligand (KMN-21) antagonist for mu/kappa heterodimeric opioid receptorsPharmacological Properties of Bivalent Ligands Containing Butorphan Linked to Nalbuphine, Naltrexone, and Naloxone at μ, δ, and κ Opioid ReceptorsPolyamidoamine (PAMAM) dendrimer conjugates of "clickable" agonists of the A3 adenosine receptor and coactivation of the P2Y14 receptor by a tethered nucleotide.Increasingly accurate dynamic molecular models of G-protein coupled receptor oligomers: Panacea or Pandora's box for novel drug discovery?Programmable nanoscaffolds that control ligand display to a G-protein-coupled receptor in membranes to allow dissection of multivalent effects.Design strategies for bivalent ligands targeting GPCRs.Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand seriesAn in Vitro and in Vivo Investigation of Bivalent Ligands That Display Preferential Binding and Functional Activity for Different Melanocortin Receptor Homodimers.A Direct in Vivo Comparison of the Melanocortin Monovalent Agonist Ac-His-DPhe-Arg-Trp-NH2 versus the Bivalent Agonist Ac-His-DPhe-Arg-Trp-PEDG20-His-DPhe-Arg-Trp-NH2: A Bivalent Advantage.GPCR ligand dendrimer (GLiDe) conjugates: adenosine receptor interactions of a series of multivalent xanthine antagonistsPNA-Based Multivalent Scaffolds Activate the Dopamine D2 ReceptorHitting multiple targets with multimeric ligands.Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance.Pharmacological Profiles of Oligomerized μ-Opioid Receptors.Peptides in receptor-mediated radiotherapy: from design to the clinical application in cancers.Rational Modification of the Biological Profile of GPCR Ligands through Combination with Other Biologically Active Moieties.Multivalent approaches and beyond: novel tools for the investigation of dopamine D2 receptor pharmacology.Effect of linker length and composition on heterobivalent ligand-mediated receptor cross-talk between the A1 adenosine and β2 adrenergic receptors.Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.An immunocytochemical-derived correlate for evaluating the bridging of heteromeric mu-delta opioid protomers by bivalent ligands.Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands.Potentiation of the antagonistic effect of ACTH11-24 on steroidogenesis by synthesis of covalent dimeric conjugates.Dopamine D2 receptors dimers: how can we pharmacologically target them?
P2860
Q28822182-933D8735-C01F-467C-8504-8C71A4F67931Q29542291-F1E216DC-992C-4CA9-BD50-5C9B67A2F08CQ33754704-57FB248D-276A-4911-975C-F97DA8A4A49AQ33767121-C9961EFB-7956-4AB7-B6D1-3A88244ED63FQ34145241-EFF4834B-A35E-46E2-A61A-164C949E76DAQ34180510-5AC89B3B-D5F5-495A-90B6-BABF0E76EC8CQ34244966-8CF67040-6FA5-4964-847D-9643DA10E276Q34517465-FCF28FC9-1148-4C05-BEC8-9697773DC5D7Q34550143-ACFDE446-1BD0-4880-8E29-5EDCE69B16A6Q35048339-C5F21C55-20DC-42EF-8CDD-6EC87628FC9AQ35379024-D464E399-759E-487D-BCC6-9AC5F16B5421Q35976363-23512DB1-2BD3-4C12-8F25-576E7F9FF62EQ37360643-16DFACE4-A95F-4F94-ABD7-4DA0B4B68302Q37679197-1FD86FB1-6AFE-4F98-91BC-C11C4D0CA81DQ38149131-F60A0709-C960-4F1F-8598-37C78F2BDF8CQ38458891-15510925-8352-490F-A353-A0FE5C188D0DQ38846984-3016AD41-BDE1-4F04-8C74-63DF09C3864CQ39084286-210E40DF-7BB5-48D5-87C8-E8CD11017AD4Q39211934-79EDEA61-D292-4A2B-9366-43CAA3FF1BD7Q41433275-A0816744-2DE9-4DD1-8D2E-7F188269DD43Q43169496-D1D6D355-98C0-402F-B9F5-845A172F9D7CQ44447476-6F828B4F-3988-43E2-99C2-93BC7FD04C6FQ50994126-3EF5B463-B220-46AF-93D8-BA0AA06E7486
P2860
Opioid agonist and antagonist bivalent ligands as receptor probes.
description
1982 nî lūn-bûn
@nan
1982 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1982 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1982年の論文
@ja
1982年論文
@yue
1982年論文
@zh-hant
1982年論文
@zh-hk
1982年論文
@zh-mo
1982年論文
@zh-tw
1982年论文
@wuu
name
Opioid agonist and antagonist bivalent ligands as receptor probes.
@ast
Opioid agonist and antagonist bivalent ligands as receptor probes.
@en
Opioid agonist and antagonist bivalent ligands as receptor probes.
@nl
type
label
Opioid agonist and antagonist bivalent ligands as receptor probes.
@ast
Opioid agonist and antagonist bivalent ligands as receptor probes.
@en
Opioid agonist and antagonist bivalent ligands as receptor probes.
@nl
prefLabel
Opioid agonist and antagonist bivalent ligands as receptor probes.
@ast
Opioid agonist and antagonist bivalent ligands as receptor probes.
@en
Opioid agonist and antagonist bivalent ligands as receptor probes.
@nl
P2093
P1433
P1476
Opioid agonist and antagonist bivalent ligands as receptor probes.
@en
P2093
Portoghese PS
Ronsisvalle G
Takemori AE
P304
P356
10.1016/0024-3205(82)90362-9
P407
P577
1982-09-01T00:00:00Z